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Adenosine A2a receptor antagonists reduce symptom severity in Parkinson disease (PD) and animalmodels. Rodent studies support the
hypothesis that A2a antagonists produce this benefit by reducing the inhibitory output of the basal ganglia indirect pathway. One way to
test this hypothesis in humans is to quantify regional pharmacodynamic responses with cerebral blood flow (CBF) imaging. That
approach has also been proposed as a tool to accelerate pharmaceutical dose finding, but has not yet been applied in humans to drugs
in development. We successfully addressed both these aims with a perfusionmagnetic resonance imaging (MRI) study of the novel
adenosine A2a antagonist SYN115. During a randomized, double-blind, placebo-controlled, crossover study in 21 PD patients on
levodopa but no agonists, we acquired pulsed arterial spin labeling MRI at the end of each treatment period. SYN115 produced a
highly significant decrease in thalamic CBF, consistent with reduced pallidothalamic inhibition via the indirect pathway. Similar
decreases occurred in cortical regions whose activity decreases with increased alertness and externally focused attention, consis-
tent with decreased self-reported sleepiness on SYN115. Remarkably, we also derived quantitative pharmacodynamic parameters
from the CBF responses to SYN115. These results suggested that the doses tested were on the low end of the effective dose range,
consistent with clinical data reported separately.We conclude that (1) SYN115 enters the brain and exerts dose-dependent regional
effects, (2) the most prominent of these effects is consistent with deactivation of the indirect pathway as predicted by preclinical
studies; and (3) perfusion MRI can provide rapid, quantitative, clinically relevant dose-finding information for pharmaceutical
development.
Introduction
Measuring the sensitivity of a biological system to a drug is of
significant interest not only as a topic of basic research, but also as
a practical tool for pharmaceutical development, since dose-
finding studies in humans are crucially important yet expensive
and often take months or years. New approaches to measuring
pharmacodynamic response are eagerly sought. One approach
has been to image the organ of interest while applying pharma-
cological stimuli (rather than cognitive tasks or sensory stimuli).
Pharmacological challenge imaging is especially relevant for
studies of the brain (Herscovitch, 2001; Wise and Tracey, 2006;
Lawrence and Mackey, 2008).
Pharmacological challenge imaging was applied very early in
preclinical studies of the action of antiparkinsonian drugs (Mc-
Culloch and Harper, 1977; McCulloch et al., 1980b), and further
studies clarified the neuronal pathways that led to the effects on
cerebral blood flow (CBF) or metabolism and their alteration
with parkinsonismor anesthestics (McCulloch, 1982;McCulloch
et al., 1980a; Crosby et al., 1982; Trugman, 1995). This approach
was extended to in vivo neuroimaging in humans (Grasby et al.,
1993; Hershey et al., 1998; Black et al., 2005) and other primates
(Perlmutter et al., 1993; Black et al., 1997; 2000; 2002a,b; Hershey
et al., 2000). Even so, few pharmacological challenge studies pro-
duced dose–response information (Grasby et al., 1993; Perlmut-
ter et al., 1993; Black et al., 1997, 2000, 2002a,b; Hershey et al.,
2000; Ireland et al., 2005; Kofke et al., 2007; Bruns et al., 2009),
and none provided quantitative characterization of a dose–re-
sponse curve.
For technical reasons, blood oxygenation level-dependent
(BOLD)-sensitive functionalmagnetic resonance imaging (fMRI) is
difficult to apply to pharmacological challenge imaging (Iannetti
andWise, 2007), though several labs have performed pharmaco-
logical challenge fMRI in nonhuman species or for drugs with a
short half-life (Chen et al., 1996, 1997, 2001; Ireland et al., 2005;
Borsook et al., 2007; Bruns et al., 2009). Blood-flowMRI does not
share the technical limitations of BOLD-sensitive methods, and
it builds on the successes of blood-flow positron emission
tomography (PET) in producing useful pharmacodynamic re-
sults (Herscovitch, 2001; Leslie and James, 2001). Recent stud-
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ies have demonstrated the validity of applying perfusion MRI in
humans to study existing drugs (Borsook et al., 2007; Kofke et al.,
2007; MacIntosh et al., 2008; Bruns et al., 2009). However, prac-
tical and physiological issues have delayed useful applications;
we have not located a published report of human pharmaco-
logical challenge perfusion MRI successfully applied to an in-
vestigational new drug.
A2a receptor antagonists are being studied eagerly as potential
alternative treatments forParkinsondisease (PD) (Fuxe et al., 2007).
A2a receptors colocalize on striatopallidal neurons with dopamine
D2 andD3 receptors, which inhibit the so-called indirect basal gan-
glia pathway from striatum to thalamus via globus pallidus pars
externa, subthalamic nucleus (STN), and internal pallidum
(Stro¨mberg et al., 2000; Torvinen et al., 2005). A2a antagonists
produce some of the same biological effects as dopamine D2 and
D3 agonists (Tanganelli et al., 2004), yet it is not known whether
they also inhibit the indirect pathway, nor which “downstream”
cortical and subcortical regions of human brain are most sensi-
tive to A2a antagonism.
We used perfusion MRI to answer these scientific questions
and to inform development of a new A2a receptor antagonist,
SYN115. This work was presented in part at the annual meetings
of the Society for Neuroscience, the American Academy of Neu-
rology, and the Movement Disorders Society (Dickerson et al.,
2009; Black et al., 2010a,b).
Materials andMethods
Regulatory approvals, registrations, and patient consent. This study was ap-
proved by the Washington University Human Research Protection Office.
Writtendocumentationof informedconsentwas
obtained inadvance fromeach subject. Levodopa
and SYN115 were given under U.S. Food and
DrugAdministration (FDA) InvestigationalNew
Drug Application 78,230.
The study was conducted at the Center for
Clinical ImagingResearch and theNeuroClini-
cal Research Unit of Washington University
School of Medicine (St. Louis, MO) and regis-
tered at http://clinicaltrials.gov (identifier,
NCT00605553).
Study participants. Twenty-one nonde-
mented, nondepressed adults age 40–75 with
mild idiopathic PD [Hoehn and Yahr (1967)
stages 1–3], treated with a stable dose of levo-
dopa but no dopamine agonists, participated
in the study. Detailed inclusion and exclusion
criteria were reported previously (Black et al.,
2010c).
Study protocol. In this crossover study, sub-
jects were randomly assigned to one of two
treatment sequences: those assigned to se-
quence 1 took SYN115 twice daily for a week,
waited 1 week (washout period), and then took
a matching placebo twice daily for a week;
those assigned to sequence 2 participated in the
reverse order (Fig. 1a). Subjects and staff were
blind to SYN115-placebo sequence assign-
ment. In 14 subjects, each SYN115 dose during
the active treatment week was 60mg, and in 12
subsequent subjects the dose was 20 mg. Five
subjects who participated in the 60 mg placebo
segment later participated in the 20mg placebo
segment, for a total of 21 distinct subjects.
Subjects were evaluated on the last day of
each treatment week (“scan days”) (Fig. 1b).
Subjects had abstained from food and all forms
of caffeine since the preceding evening. On the
morning of the scan day, they did not take their usual antiparkinsonian
medications, but they took the last dose of SYN115 or placebo at approx-
imately 6:00 A.M. After arrival at the imaging center, subjects took 200
mg of carbidopa by mouth and then underwent two sets of clinical and
MRI assessments, once before and once during an infusion of levodopa.
The intravenous levodopa infusion was dosed so as to rapidly produce
and then maintain a steady plasma concentration of 600 ng/ml (Gordon
et al., 2007). The infusion was delivered through small-bore light-
resistant Luer lock tubing (part 537235PS; Medex) from a model 44
syringe pump (Harvard Apparatus) inside an RF-shielded copper box
(Shielding Resources Group). The time-dependent infusion rate was
controlled by custom software written in Java (Sun Microsystems) run-
ning on a small solid-state laptop computer (Eee PC 2G; Asus) connected
to the pump’s serial port. The pump was powered through an uninter-
ruptible power supply (battery backup) inside the copper box so that the
pump box could be moved with the patient without interrupting the
infusion.
AllMRI and clinical assessments were repeated while themaintenance
levodopa infusion continued, beginning at least 25 min after the levo-
dopa infusion started, i.e., after4 the distribution half-life (t1/2) of
intravenous levodopa (Abraham et al., 2006). Blood samples formeasur-
ing plasma levodopa concentrations were taken from an upper extremity
vein contralateral to the infusion site after the second assessment battery
of each day.
The timing of the clinical and fMRI assessments before and on levo-
dopa was planned to approximately bracket the Tmax of SYN115 (time to
maximal plasma concentration) after chronic dosing.
Behavioral state during fMRI scans. Each assessment batterymentioned
above included eight perfusion MRI scans. Each perfusion scan was ac-
quired during a single behavioral task condition: two scans while the
subject fixated a central crosshair surrounded by a circular checkerboard
Figure 1. Study design (see Materials and Methods, Study Protocol for important details). a, Top, Schematic showing the
temporal relationship of each subject’s scan days to his or her taking active study drug and placebo.b, Bottom, Schematic showing
each subject’s participation on each of his or her two scan days. LD, Levodopa.
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pattern reversing at 8 Hz, two scans while the subject performed a two-
back letter working memory task, and four control visual fixation scans
with the crosshair but no checkerboard. The reversing checkerboard
scans were done as a positive control for the arterial spin labeling (ASL)
method so that if the study drug showed no activation we could test
whether ASL, as implemented in this study, was adequately sensitive to
changes in regional CBF (rCBF).
Quantification of plasma concentration of SYN115. SYN115 plasma con-
centrations were determined using a validated high-performance liquid
chromatography/tandemmass spectrometry (HPLC-MS/MS)assay (Front-
age Laboratories). The method used protein precipitation of SYN115 from
human plasma followed by HPLC separation andMS/MS detection, with a
deuterated internal standard. Electrospray ionization and positive sample
modewere usedon anAPI 4000 and5000platform.All sample analysis runs
used freshly prepared quality control samples. The assaywas validated in the
concentration range of 10–10,000 ng/ml.
MRImethods.AllMRI data were acquired on the Siemens 3.0TTimTrio
with a matrix head coil. ASL images were acquired with the commercial
Siemens pulsed ASL sequence (Wang et al., 2003) with 15 echoplanar read-
out slices parallel to the bicommissural line, at a center-to-center distance of
6.0mm,6464voxels inplanewithdimensions (3.4375mm)2, a repetition
time (TR) of 2.6 s, an echo time (TE) of 13.0ms, and a flip angle of 90°. An
M0 imagewas followed by 31 tag-control pairs for a total acquisition time
for each ASL “scan” of 2.73 min. Brain structure was assessed by averag-
ing two mutually registered sagittal magnetization-prepared rapid-
acquisition gradient echo acquisitions with a voxel size of (1.0mm)3, TR
of 2.4 s, TE of 3.08 ms, inversion time of 1000 ms, and flip angle of 8°.
Creation of scaled CBF images. The 63 frames of the ASL run were
rigidly aligned using a validatedmethod (Black et al., 2001) and summed
to facilitate later alignment steps. Each frame was smoothed using a
Gaussian filter with kernel measuring 7.35 mm [full-width at half-
maximum (FWHM)], and CBF was computed in each voxel for each
tag-control pair (Wang et al., 2003). The summed within-run-aligned
echoplanar images were mutually aligned within each subject and
summed, and the resulting image was affine registered to a target image
in Talairach and Tournoux space made using validated methods from
the structural MR images from these subjects (Black et al., 2004). From
this registration, the 31 tag-control-pair CBF imageswere resampled into
atlas space using matrix multiplication to avoid multiple resampling
steps and averaged to create a single atlas-registered CBF image for each
ASL run. One such image is shown in supplemental Figure 6 (available at
www.jneurosci.org as supplemental material).
Only those voxels were analyzed that were represented in every echop-
lanar image in every subject. The combined volume of these voxels was
1,231 ml (supplemental Fig. 7, available at www.jneurosci.org as supple-
mental material). Global or whole-brain mean CBF (gCBF) was com-
puted across these voxels so that gCBF was computed from the same
brain region in every scan in every subject. However, for a given scan,
voxels whose value was20 or120ml  hg1  min1 (i.e., physiolog-
ically unreasonable values) were excluded from this mean.
Regional analyses must account for possible changes in gCBF with
drug to avoid incorrectly interpreting results (Black et al., 2002b). Thus,
all analyses examining regional CBF removed the gCBF effect by scaling
all input images multiplicatively so that the global mean CBF for every
image was 50 ml  hg1  min1. This conventional approach to blood-
flow imaging was prespecified for this study from the outset. Thus, any
decreases in regional CBF represent changes beyond that which could be
explained by the overall change in whole-brain average, or global, CBF.
Statistical methods. Our lab’s standard approach to pharmacological
activation analysis is to perform a voxelwise statistical parametric map-
ping (SPM) analysis to identify regional changes, using globally scaled
CBF images only from placebo and the highest dose of drug (Black et al.,
2004). This approach reduces themultiplicity of possible comparisons by
assuming that the drug effects ofmost interest are those that are largest in
magnitude (or most consistently present) at the highest dose of drug.
Regions identified as having significantly altered rCBFwith drug are then
examined in images from lower doses.
In this study, we used a two-level, mixed-effects approach to analysis
with the goal of identifying only effects likely to be representative of the
entire population from which our subjects were sampled (Gla¨scher and
Gitelman, 2008). First, for each subject in the study, changes in rCBF
were identified from the 60 mg study arm using SPM8 software (www.
fil.ion.ucl.ac.uk/spm/) and a voxelwise general linear model that in-
cluded factors representing study drug (SYN115 vs placebo), levodopa
(before vs during infusion), the drug by levodopa interaction, and task
(i.e., behavioral state during the scan: two-back working memory, 8 Hz
reversing circular checkerboard, or visual fixation). A statistical paramet-
ric image for each subject was generated from the drug contrast and a
second one from the drug by levodopa contrast.
Statistical inference for the entire study was done across subjects in a
second-level SPM analysis. The contrast images generated for each sub-
ject as described in the preceding paragraph were the input data for a
voxelwise general linear model that included a covariate for subject age
(in years) and factors for subject sex (male, female) and dose of SYN115
in the active capsules (20 or 60 mg). Statistical inference was performed at
each voxel with a one-sample t test (i.e., testing across subjects whether the
drug contrast subject images are significantly less than or greater than zero).
Multiple-comparisons correction was performed at the cluster level
with the false discovery rate set at p 0.05, according to our prespecified
analysis strategy. However, to minimize type II error, we also list in
supplemental Table 3 (available at www.jneurosci.org as supplemental
material) all peaks with uncorrected p values0.001.Highlighted entries
in this table indicate peaks that would be considered significant by a
different statistical criterion, such as single-voxel (magnitude-based)
false discovery rate correction. In this data set, the Bonferroni correction
would accept as significant all voxels with t 4.8.
Approximate anatomical locations were provided by the Talairach
Daemon client (www.talairach.org) (Lancaster et al., 2000), with correc-
tions by reference to the study-specific MRI template atlas image.
Image sampling and VOI definition. Local maxima (“peaks”) from sig-
nificant clusters were selected for additional analysis. Mean rCBF values
representing each peak were derived from a 12-mm-diameter spherical
VOI centered at the peak. This diameter corresponds to the 10–12 mm
resolution (FWHM) of the data as estimated by SPM. These VOIs were
masked to include only voxels with t values exceeding the value corre-
sponding to p 0.001 (uncorrected) and only voxels represented in the
final mask (supplemental Fig. 7, available at www.jneurosci.org as sup-
plemental material).
Pharmacodynamic parameter estimation. We estimated the classic
pharmacodynamic parameters Emax (maximal effect) and EC50 (drug
concentration in plasma that produces an effect equal to 50%  Emax)
using custom software by Bretthorst (1988) that implements a Markov
chain Monte Carlo simulation method. The equation is E(C) E(0)
Emax  C
n / (EC50
n  Cn), where n is the Hill coefficient (unitless) that
controls the steepness of the sigmoid curve. The independent variable C
is the plasma concentration in nanograms per milliliter of SYN115 sam-
pled in the prelevodopa or on-levodopa state in which the corresponding
ASL images were obtained. The dependent variable E, effect of drug, was
each subject’s fractional change in mean rCBF in the VOI centered at the
SPM peak, relative to the prelevodopa value from that subject’s placebo
day (Eli Lilly and Company andNIHChemical Genomics Center, 2008).
Data from the 20 and 60mg armswere considered together. Prior probabil-
ities are given in supplemental Table 4 (available at www.jneurosci.org as
supplemental material). The appropriateness of the pharmacodynamic
model to these datawas quantified by the probability that it better explained
the data than a polynomial with the same number of free parameters.
Results
Every subject who took any dose of study drug or placebo com-
pleted every scheduled MRI scan at every assessment session,
except for one subject whowas discharged from the 20mg arm of
the study on the morning of the first assessment day because of
noncompliance. This subject had already participated without
error in the 60 mg arm but is not counted in the 12 subjects who
completed the 20 mg arm. Thus, for all included subjects, all
scheduled CBF scans were included in the analyses, for a total of
832 CBF scans (derived from 52,416 echoplanar image volumes).
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Subjects were, on average, 60.8 years old (range, 44–73), had a
5.3 year mean duration of PD symptoms (range, 0.9–10.8), and
12 of the 21 had ever experienced dopa-induced dyskinesias. All
were Caucasian and right-handed, and 8 of the 21 were women.
Compliance was excellent as assessed by pill counts. The levo-
dopa infusion produced plasma concentrations of 816  168
ng/ml (mean  SD), and plasma concentrations did not differ
significantly between conditions (t test, p 0.20).
Whole-brain blood-flow effects
SYN115 induced a small dose-dependent decrease inmean global
CBF (20 mg, p.o., b.i.d., mean 4%, p 0.001 by paired t test; 60
mg, p.o., b.i.d., 7%, p  0.001). As noted
in Materials and Methods, this change in
gCBFwith the drugwas removed from the
images before proceeding to the analyses
described below.
Decreases in rCBF with SYN115
SYN115 induced highly significant de-
creases in regional CBF. Eight clustersmet
the predefined criteria for statistical sig-
nificance after correction for multiple
comparisons (Table 1). The first cluster
(corrected p 1031) had its peak t value
in thalamus but also extended into mid-
brain, precuneus, cuneus, and cerebellum
(Fig. 2a,d). Volumes of interest (VOIs)
from seven t value localmaxima (“peaks”)
from this cluster were selected for addi-
tional analysis (left and right thalamus,
left and right midbrain, precuneus [Brod-
mann’s area (BA) 7, BA 31], and posterior
cingulate [BA 30]), as described in Mate-
rials and Methods; atlas coordinates for
the center of eachVOI are given in supple-
mentalTable3(availableatwww.jneurosci.
org as supplemental material). Figure 2c
highlights the peak voxel from cluster 2.
For completeness, supplemental Table 3
(available at www.jneurosci.org as supple-
mental material) lists every local maximum
in the thresholded t image that was sepa-
rated from other maxima by 8 mm). To
check the specificity of our results, we re-
peated the analysis using only those CBF
scans acquired off levodopa during the vi-
sual fixation condition; results were similar
(supplemental Fig. 8, available at www.
jneurosci.org as supplemental material).
As mentioned, the most statistically significant decreases in
blood flow with 60 mg b.i.d. SYN115 occurred in bilateral thala-
mus (Fig. 2a). The rCBF changes at these regionswere dose respon-
sive (Fig. 2b). The decreases in the right thalamus VOI were even
larger in the original images, before removing the whole-brain
(mean global) CBF decrease (20mg,10.4%; 60mg,19.0%).
Dose responsiveness of rCBF decreases
The regions with decreased rCBF were identified using only the
images acquired in subjects who took the higher dose of SYN115.
Nevertheless, across the 20 VOIs listed in Table 2, the rCBF de-
creases were consistently greater in magnitude at the higher dose
Figure 2. a, Statistical image (color) representing the t values from the contrast (rCBF on SYN115 60 mg, b.i.d.) (rCBF on
placebo), laid over the study-specificMRI template image (grayscale). The right side of thebrain is displayedon the right side of the
coronal image and the bottom of the axial image. The color t image shows all voxels for which t 4.03 (corresponding to p
0.001, uncorrected). The orthogonal hairlines in each cross section identify the location of the other two cross sections and cross at
the voxel in right thalamuswith thehighest t in thewhole image (19.51; 11df).b, Dose-dependent decrease in rCBFwith SYN115
in the right and left thalamus VOIs defined as described inMaterials andMethods. c,d, The same image and conventions described
in a, with different cross sections chosen to display other peak t values. c, Hairlines cross at the peak t value from cluster 2. d,
Hairlines cross at the local peak that defined VOI 3 from cluster 1 (in precuneus). For coordinates and anatomical descriptions, see
Table 1 and supplemental Table 3 (available at www.jneurosci.org as supplemental material).
Table 1. Significant decreases in rCBF on the higher dose of SYN115 compared with placebo
Cluster Volume of cluster (in ml) Peak t value (11 df) Location of peak t value Anatomic description of cluster
1 51.4 19.51 Right dorsomedial thalamus Bilateral thalamus, precuneus (BA 7, 23, 31), midbrain, cuneus
(BA 7, 18), posterior cingulate (BA 23, 29, 30)
2 12.1 14.27 Right anterior cingulate cortex (BA 32) Bilateral anterior cingulate (BA 32), medial frontal gyrus (BA 9, 11)
3 9.7 9.59 Left prefrontal cortex (lateral to BA 32) Left middle and inferior gyri (BA 8, 9, 45, 46), precentral gyrus (BA 44)
4 8.7 7.74 Left middle frontal gyrus (BA 6) Left middle and precentral gyri (BA 6, 4)
5 2.8 6.81 Right postcentral gyrus (BA 2) Right postcentral gyrus (BA 2)
6 2.8 6.71 Left superior parietal lobule (BA 7) Left superior parietal lobule (BA 7)
15 1.4 5.45 Right precentral gyrus (BA 6) Right precentral and medial frontal gyri (BA 6)
22 0.9 4.90 Right medial frontal gyrus (BA 9) Right medial frontal gyrus (BA 9)
See supplemental Table 3 (available at www.jneurosci.org as supplemental material) for additional details.
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than at the lower dose (before levodopa, 18 of 20 VOIs; after
levodopa, 20 of 20VOIs).Weperformed secondary SPManalyses
to test whether this dose-responsive pattern was an artifact of
selecting the VOIs from the higher-dose group only and con-
cluded that it was not (results from an analysis of the five subjects
who had data from both doses of active drug are given in supple-
mental Table 5, available at www.jneurosci.org as supplemental
material, and results from a similar analysis across both dose
groups are in supplemental Table 6, available at www.jneurosci.
org as supplemental material).
Quantifying SYN115 potency
The placebo/20 mg/60 mg dose–response plot does not allow
estimation of EC50. We exploited the inherent pharmacokinetic
variability across subjects to create a group concentration-
response curve (Fig. 3) for the rCBF change in each of the VOIs
identified in supplemental Table 3 (available at www.jneurosci.
org as supplemental material) and Table 2. We summarize here
the results from thalamus and midbrain VOIs. In each case, the
pharmacodynamic model was the more appropriate model
(probability, 92–100%) (Table 2). In the before-levodopa state,
the estimated maximum possible SYN115 effect on rCBF (Emax)
was a 29–30% decrease in thalamus and a 15–32% decrease in
midbrain. Left midbrain (near superior colliculus; EC50  202
ng/ml) was more sensitive than thalamus (EC50  942–966 ng/
ml) and right midbrain (near substantia nigra pars reticulata and
pons, 1044 ng/ml). The Hill coefficient n was1 for these VOIs,
indicating a gradual increase in signal magnitude as blood con-
centration rises (Fig. 3, open double-line curve). The model as-
cribed a small effect on blood flow in these regions to levodopa
itself (indicated by the nonzero E0 entries in Table 2). In scans
acquired during the levodopa infusion, the rCBF response to
SYN115 changedmore sharply over a narrower range of SYN115
concentrations (n 4.03–7.10) (Fig. 3, solid curve), and thus the
concentrations actually observed in our study came closer to pro-
ducing the maximal predicted rCBF response (Emax).
Increases in rCBF with SYN115 and levodopa effects
No statistically significant clusters were found for relative in-
creases in rCBF with SYN115 or for the drug by levodopa inter-
action. The study was not designed to examine changes in rCBF
with levodopa, and an SPM analysis found no significant de-
creases, but rCBF increased significantly with levodopa in one
small cluster with peak values in the right putamen, claustrum,
and insula (supplemental Table 8, available at www.jneurosci.org
as supplemental material).
Discussion
The A2a antagonist SYN115 substantially decreased CBF in me-
diodorsal thalamus, midbrain, precuneus, and cingulate cortex.
Since direct vascular effects would apply to all regions of the
brain, the most likely explanation for the regionally specific CBF
effects is that SYN115 crosses the blood–brain barrier and alters
neuronal firing. The dose-responsive nature of the rCBF effects
Table 2. Pharmacodynamic parameters calculated from SYN115 blood levels and corresponding rCBF changes
SYN115 only SYN115 levodopa
VOI Atlas coordinate Name EC50 Emax n Prob. model Prob. poly EC50 Emax n E0 Prob. model Prob. poly
1 10.5 21 12 Right thalamus 966 30 0.95 0.94 0.06 917 16 4.03 1.8 0.96 0.04
2 7.5 18 12 Left thalamus 942 29 1.07 0.92 0.08 779 15 7.10 1.2 1.00 0.00
3 13.5 66 36 Precuneus, BA 7 460 13 8.47 0.96 0.04 1113 17 1.85 2.6 0.96 0.04
4 1.5 33 3 Midbrain 202 15 1.05 0.92 0.08 1344 12 4.24 2.5 0.94 0.06
5 19.5 69 18 Precuneus, BA 31 220 7 2.34 0.88 0.13 495 11 8.32 1.2 0.96 0.04
6 10.5 27 15 Midbrain 1044 32 1.78 1.00 0.00 1018 21 4.31 1.9 0.98 0.02
7 4.5 51 18 Posterior cingulate, BA 30 208 15 0.80 0.88 0.13 947 7 4.11 7.1 0.98 0.02
8 7.5 45 9 Anterior cingulate, BA 32 717 12 7.88 0.98 0.02 713 15 9.79 1.0 1.00 0.00
9 1.5 30 33 Medial frontal gyrus, BA 9 699 8 7.45 0.92 0.08 831 3 1.71 6.4 0.96 0.04
10 10.5 45 12 Medial frontal gyrus, BA 11 808 6 1.62 0.98 0.02 939 9 3.27 0.6 0.98 0.02
11 4.5 12 33 Cingulate gyrus, BA 32 1449 12 3.51 0.98 0.02 1525 9 3.05 2.0 0.98 0.02
12 7.5 21 39 Middle frontal gyrus, BA 8 825 20 1.45 0.92 0.08 1031 10 2.42 4.9 0.98 0.02
13 4.5 6 51 Middle frontal gyrus, BA 6 1080 18 2.44 0.96 0.04 874 19 3.33 1.2 0.98 0.02
14 7.5 36 60 Postcentral gyrus, BA 2 643 14 1.13 0.90 0.10 1281 25 3.89 2.2 1.00 0.00
15 7.5 60 63 Superior parietal lobule, BA 7 623 14 2.07 0.96 0.04 829 11 3.33 2.3 0.98 0.02
16 7.5 78 12 Cuneus, BA 17 210 7 1.50 0.92 0.08 465 8 7.30 1.2 0.96 0.04
17 4.5 33 9 Parahippocampal gyrus, BA 36 625 6 6.06 0.98 0.02 664 9 1.83 2.7 0.98 0.02
18 13.5 15 63 Precentral gyrus, BA 6 1014 17 2.92 0.96 0.04 716 34 2.83 9.1 1.00 0.00
19 13.5 9 18 Temporal lobe, BA 20 502 15 2.77 0.98 0.02 1138 21 3.70 1.0 1.00 0.00
20 16.5 15 3 Head of right caudate 541 13 3.36 0.94 0.06 984 21 5.15 0.1 1.00 0.00
For details, seeMaterials andMethods, Pharmacodynamic parameter estimation. LD, Levodopa; Prob.model, probability of full model; Prob. poly, probability of polynomial. For VOIs, numbers are from the penultimate column in supplemental Table 3
(available atwww.jneurosci.org as supplementalmaterial); for example, VOI 8 is centered at the peak t value in cluster 2.
Figure 3. The pharmacokinetic variability across subjects was exploited to create a popula-
tion dose–response curve for the rCBF change in the right dorsomedial thalamus VOI. For addi-
tional details, see Results, Quantifying SYN115 potency for decreasing rCBF as a function of
plasma concentration.
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strongly suggests that they reflect pharmacological effects of
SYN115 in the brain.
PerfusionMRI in pharmaceutical development
The results answer the primary questions posed in the introduc-
tion: SYN115 causes pharmacodynamic effects in the brain, and
they are greater at the higher dose. The quantitative EC50 esti-
mates (Fig. 3, Table 2) suggest that an even higher dose may be
more effective in terms of thalamic CBF response and perhaps
also clinically. Confirmation of that hypothesis will require a
large clinical study, but in this study a measure of motor speed
improved significantly only on the higher dose of SYN115 (Black
et al., 2010c).
Kofke et al. (2007) reported CBF effects of remifentanil, an
FDA-approved opioid agonist, at three doses in six human brain
regions chosen a priori, and similar results were reported in other
species (see Introduction). However, to our best knowledge, no
previous pharmacological challenge neuroimaging study has cal-
culated quantitative EC50 values.
Physiological interpretation
An important question is which neurons are responsible for these
rCBF changes. Numerous studies provide evidence that the met-
abolic response to stimulation of a neuron occurs primarily at the
axon termini (Buzsa´ki et al., 2007), including a [18F]fluorodeoxy-
glucose PET study in PD patients whose globus pallidus internal
segment electrical activity was measured invasively (Eidelberg et
al., 1997). Thus, rCBF changes most likely reflect changes in the
firing of afferent neurons. With this principle in mind, Figure 4
shows how the known pharmacology and anatomy of the basal
ganglia predict this study’s most significant result (supplemental
Table 7, available at www.jneurosci.org as supplemental mate-
rial). These results also accord with an 8–12% increase in tha-
lamic glucose metabolism in untreated PD and the reduction of
this increase by antiparkinsonian treatments (Ma et al., 2009).
After thalamus, the brain regions most significantly affected
by SYN115 were the anterior cingulate (BA 32) and precuneus
(BA 7, BA 23, and BA 31) (Fig. 2c,d; supplemental Table 3, avail-
able at www.jneurosci.org as supplemental material). The precu-
neus has several distinctive properties: in the fully awake alert
state, it consumes35%more glucose by weight than any other
human cortical region (Gusnard et al., 2001), and its metabolism
and rCBF decrease markedly in various states of reduced or ab-
sent consciousness (e.g., slow-wave sleep, propofol-induced an-
esthesia, and vegetative states) (Cavanna and Trimble, 2006).
This may be relevant since SYN115 at 60 mg p.o. b.i.d. decreased
self-reported sleepiness (Campbell et al., 2010). The precuneus
and anterior cingulate are also key components of the default-
mode network, a network of brain regionswith high tonic activity
at rest that is significantly attenuated during goal-directed tasks
(Raichle et al., 2001). Dopamine D2 and D3 agonists reduced
rCBF in these regions (Fig. 5), and a recent report suggested a
dopaminergic link between attention and precuneus deactivation
(Tomasi et al., 2010). In fact, an fMRI study reported anomalous
precuneus and adjacent posterior cingulate responses in PD pa-
tients, compared to control subjects, during performance of an
executive function task (van Eimeren et al., 2009).
Comparison with caffeine effects
Most existing data on CBF effects of adenosine blockade come
from studies of the nonspecific adenosine receptor antagonist
caffeine. Caffeine has complex effects on cerebral metabolism and
blood flow, so it is important to consider how, or whether, they
inform interpretation of the results with a specific A2a antagonist.
Adenosine increases CBF (Joshi et al., 2002), whereas caffeine
decreases CBF by 30% (Cameron et al., 1990; Perthen et al.,
2008). This CBF decrease is fairly uniform throughout the brain
(Mathew et al., 1983; Mathew and Wilson, 1985; Gotoh et al.,
2001; Cameron et al., 1990) and unrelated to changes in respira-
tion (Cameron et al., 1990; Mathew et al., 1983). This effect has
been detected with ASL (Laurienti et al., 2003; Liu et al., 2004;
Bendlin et al., 2007; Perthen et al., 2008). Metabolic studies show
that direct vascular effects may produce this CBF decrease, since
caffeine actually increased glucose utilization (Grome and Ste-
Figure 4. Expected effects in the indirect pathway of giving an A2a antagonist. See also
Discussion, Physiological interpretationof results, and supplemental Table 7 (available atwww.
jneurosci.org as supplemental material). GPe, Globus pallidus, pars externa; GPi, globus palli-
dus, pars interna. Figure 5. Regional CBF responses to levodopa and to specific dopamine receptor agonists
fromprevious studies. Note themidbrain response in all studies and the thalamus and posterior
cingulate responses in the D2 and D3 agonist studies. a, Levodopa/carbidopa in PD and healthy
controls (Hershey et al., 1998). b, Levodopa/carbidopa in advanced PD (Black et al., 2005). c,
Levodopa/carbidopa in baboon (Hershey et al., 2000). d, Dopamine D1 agonist SKF82958 in
baboon (Black et al., 2000). e, Dopamine D2 agonist U91356a in baboon (Black et al., 2002a). f,
Dopamine D3 D2 agonist pramipexole in baboon (Black et al., 2002b). c and d are from
additional, unpublished analyses of the data collected for the publications named above.
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fanovich, 1986; Schroeder et al., 1989; Nehlig et al., 1994; Gotoh
et al., 2001). This uncoupling of CBF from metabolism led to a
period of interest in the use of caffeine as a BOLD signal booster,
though later work has been less enthusiastic. The uncoupling is
likelymediated by adenosine receptors, since another nonspecific
antagonist replicated the effect (theophylline) (Grome and Ste-
fanovich, 1986). For these reasons, cerebral metabolism may be
more informative than CBF about the effects of caffeine on local
neuronal activity. Regional effects of caffeine on cerebral glucose
metabolism are strongest and most potent in dopamine-
influenced brain regions such as habenula, caudate, ventral teg-
mental area, amygdala, and medial and lateral thalamus (Nehlig
et al., 1994; Nehlig and Boyet, 2000, their Table 2; Gotoh et al.,
2001, their Fig. 3).
However, caffeine’s effects probably differ substantially from
those of specific A2a antagonists. Themetabolic increases induced
by caffeine appear to be mediated by A1 receptors on neurons,
whereas its global effects on blood flow are likely mediated by
vascular A2a receptors (Blood et al., 2003; Kochanek et al., 2005).
This mechanism is presumably responsible for the modest global
decrease in CBF caused by SYN115.
Regional brain effects of specific A2a antagonists
Crucially, A2a receptors also occur on neurons, and selective A2a
antagonists exert clinical, electrophysiological, and metabolic ef-
fects. Therefore, one also expects regionally specific CBF effects
caused by the neuronal actions of the drug, and these must be
identified separately from the known direct vascular effects,
which are global in nature. We contend that we have accom-
plished this for the first time in humans in the present study, but
data from other species support our results. The A2a antagonist
DMPX (3,7-dimethyl-1-propargylxanthine) decreased glucose
utilization in the rodent globus pallidus (Nehlig et al., 1994),
consistent with the finding that A2a antagonists reduce striatopal-
lidal firing (Stro¨mberg et al., 2000). DMPX also decreased re-
gional blood volume by 6–10% in thalamus, striatum, and
olfactory tubercle (Chen et al., 2005).
The rCBF changes shown in Figure 2 are comparable to those
seen in 2DG and PET studies of dopamine agonists or levodopa
(Fig. 5). The regions of brainmost sensitive toD2 andD3 receptor
agonists included midbrain, posterior cingulate cortex, prefron-
tal cortex, striatum, and thalamus (Trugman et al., 1991;Hershey
et al., 1998, 2000; Black et al., 2000, 2002b, 2005). This correspon-
dence may be expected given that A2a antagonists are thought to
produce antiparkinsonian activity via facilitation of dopamine
D2/D3 receptor effects.
Limitations
Crossover trial designs are susceptible to carryover effects. How-
ever, carryover effects are very unlikely in this study: on the pla-
cebo day, subjects either received no previous SYN115 or
discontinued it20 half-lives earlier.
Although the most significant result, decreased thalamic
rCBF, is consistent with inhibition of the indirect pathway, that
model does not predict all our results. No significant rCBF in-
crease was detected in the STN, though partial volume effects
may have hindered detection of CBF changes in this small nu-
cleus (Borghammer et al., 2009). Furthermore, the classical basal
ganglia model does not predict the rCBF decrease observed in
cortex. However, neither does it predict the similar cortical rCBF
decrease observed with D2 and D3 dopamine agonists (Fig. 5e,f).
This observation lends credence to the idea that cortical rCBF
responses are more complex than the indirect pathway model
alone can predict. After all, most cortical areas receive input from
cortical areas including homologous contralateral cortex and lo-
cal recurrent axons and interneurons (supplemental Table 7,
available at www.jneurosci.org as supplemental material). One
may even speculate that the cortical rCBF changes found in this
study may prove to have predictive value in identifying medica-
tions with effects similar to those of dopamine D2 and D3
agonists.
Study participants self-selected for willingness to participate
in research and met strict exclusion criteria. Nevertheless, they
are clinically typical and had a range of levodopa dosing and
comorbid conditions, so these results probably reflect early stage
PD generally. The study also excluded patients taking dopamine
agonists, but this exclusion strengthens confidence in our inter-
pretation that SYN115 itself is responsible for the pallidothalamic
inhibition seen here, rather than a possible interaction of SYN115
with a long-acting D2/D3 agonist.
Finally, we studied patients exposed to SYN115 for 1 week,
and single doses or chronic dosing may show additional or dif-
ferent effects. These limitations should be balanced against the
strengths of this work, including careful experimental design and
a conservative statistical analysis.
Implications
These results suggest hypotheses about how adenosine A2a antag-
onists may exert antiparkinsonian or alerting effects and identify
brain regions to which electrophysiological methods may be di-
rected to test these hypotheses. Additionally, these results dem-
onstrate the potential for pharmacological challenge perfusion
imaging to jump-start human dose selection in pharmaceutical
development. This study provided dose-finding information
quite rapidly compared with a typical clinical trial, and from
relatively few subjects.
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